Phenazopyridine Hcl

Phenazopyridine Hcl

Phenazopyridine Hcl Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Phenazopyridine hydrochloride is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals (IARC 1980, 1982, 1987, NCI 1978). When administered in the diet, phenazopyridine hydrochloride increased the incidences of hepatocellular adenomas and carcinomas in female mice and adenomas and adenocarcinomas of the colon and rectum in rats of both sexes.

There is inadequate evidence for the carcinogenicity of phenazopyridine hydrochloride in humans (IARC 1987). In one limited epidemiological study, no significant excess of any cancer was observed among 2,214 patients who received phenazopyridine hydrochloride and were followed for a minimum of 3 years.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.

The use of phenazopyridine for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy.

Phenazopyridine is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection.

Treatment of a urinary tract infection with phenazopyridine should not exceed 2 days. There is no evidence that the combined administration of phenazopyridine and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration.)

History

There is currently no drug history available for this drug.

Other Information

Phenazopyridine Hydrochloride is a reddish-brown, odorless, slightly bitter, crystalline powder. It has a specific local analgesic effect in the urinary tract, promptly relieving burning and pain.

Following is the structural formula:

50874ab0-figure-01

Phenazopyridine HCl tablets contain the following inactive ingredients: Corn Starch, Croscarmellose Sodium, Hypromellose, Light Mineral Oil, Magnesium Stearate, Microcrystalline Cellulose, Povidone, Pregelatinized Starch, and Silicon Dioxide.

Phenazopyridine Hcl Manufacturers


  • Boca Pharmacal, Inc
    Phenazopyridine Hcl Tablet [Boca Pharmacal, Inc]
  • H.j. Harkins Company, Inc.
    Phenazopyridine Hcl Tablet [H.j. Harkins Company, Inc.]
  • Bryant Ranch Prepack
    Phenazopyridine Hcl Tablet [Bryant Ranch Prepack]
  • A-s Medication Solutions Llc
    Phenazopyridine Hcl Tablet [A-s Medication Solutions Llc]
  • Preferred Pharmaceuticals, Inc
    Phenazopyridine Hcl Tablet [Preferred Pharmaceuticals, Inc]

Login To Your Free Account